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Summary
ErbB2 is a ligand-less member of the ErbB receptor family that functions as a coreceptor with EGFR, ErbB3, and ErbB4.
Here, we describe an approach to target ErbB2’s role as a coreceptor using a monoclonal antibody, 2C4, which sterically
hinders ErbB2’s recruitment into ErbB ligand complexes. Inhibition of ligand-dependent ErbB2 signaling by 2C4 occurs in
both low- and high-ErbB2-expressing systems. Since the ErbB3 receptor contains an inactive tyrosine kinase domain, 2C4
is very effective in blocking heregulin-mediated ErbB3-ErbB2 signaling. We demonstrate that the in vitro and in vivo growth
of several breast and prostate tumor models is inhibited by 2C4 treatment.
Introduction pression is the outcome of a specific molecular alteration, i.e.,
ErbB2 gene amplification that results in excess protein synthesis
The ErbB or HER signaling network is a receptor-ligand system (Slamon et al., 1987). The accumulation of excess ErbB2 at the
that is composed of four receptors and at least eleven ligands plasma membrane results in constitutive receptor activation due
(Yarden and Sliwkowski, 2001). In general, receptor expression to receptor self-association. Constitutive ErbB2 signaling is
occurs in the epithelium, whereas ligands are produced in the thought to drive tumor growth. The availability of ErbB2 at the
mesenchyme. Since these ligands are synthesized as mem- tumor cell surface allows the receptor to be targeted by trastuzu-
brane bound proforms, ligand processing and release are tightly mab. Although a number of explanations have been put forward
regulated processes. In any particular tissue the receptors are to help explain trastuzumab’s clinical benefit, the precise mech-
rarely, if ever, expressed alone, and as a result ErbB2 is fre- anism of action in any particular patient is still not completely
defined. At present two primary mechanisms are thought toquently activated due to its role as a common coreceptor. An
interesting feature of the ErbB system is that it is frequently account for trastuzumab’s clinical benefit (Sliwkowski et al.,
1999). The first is strictly biological and requires engagementcoopted by various hyperproliferative diseases including cancer
(Shawver et al., 2002), psoriasis (Ben-Bassat and Klein, 2000), of ErbB2 receptors with the bivalent antibody, which, in turn,
results in receptor downmodulation and inhibition of aberrantand vascular restenosis (Kalmes et al., 2000). As a result, two
of these receptors, EGFR and ErbB2, are targets for drug devel- receptor tyrosine kinase signaling. A second mechanism of ac-
tion is thought to occur from the interaction of trastuzumab’sopment particularly in a number of solid tumors (Arteaga, 2001).
One example is trastuzumab (Herceptin), a humanized variant human Fc region with immune effector cells (Clynes et al., 2000).
Regardless of whether either or both of these mechanisms areof the 4D5 monoclonal antibody directed against ErbB2, which
is overexpressed in a subset of human breast cancers (Cobleigh needed for a meaningful clinical outcome, treatment response
is strictly dependent on high ErbB2 expression in the tumor. Anet al., 1999; Slamon et al., 2001). In these cases, ErbB2 overex-
S I G N I F I C A N C E
The ErbB or HER receptor network is frequently dysregulated in a number of solid tumors. Breast cancers containing ErbB2 overexpression
can be treated with the ErbB2 antibody, trastuzumab (Herceptin). However, trastuzumab is only effective against high-ErbB2-expressing
tumors. In this report, we target ErbB2’s role as a coreceptor with other ErbB family members using another monoclonal antibody,
2C4. In contrast to trastuzumab, 2C4 disrupts ErbB2’s association with other ErbB receptors and inhibits ligand-stimulated signaling
in tumor cells that express lower ErbB2 levels. Potential therapeutic benefit of 2C4 treatment does not require the antibody to contain
an intact Fc region and is observed in human breast and prostate cancer models, which do not overexpress ErbB2. Humanization
of 2C4 will allow for assessment of its potential clinical utility.
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alternative immunotherapy approach is taken with the closely
related EGFR. Here, antibodies are selected to inhibit ligand
binding and subsequent downstream receptor signaling (Men-
delsohn and Baselga, 2000).
Disruption of EGFR signaling can also be accomplished with
compounds that inhibit the intrinsic tyrosine kinase activity of
the receptor (Woodburn, 1999). In particular, quinazolines, such
as ZD-1839 or CPI-358,774, which compete with one of the
kinase substrates, ATP, appear to be promising clinically be-
cause they exhibit the requisite specificity for EGFR, are orally
bioavailable, and have been generally well-tolerated to date in
clinical trials (Baselga and Averbuch, 2000; Hidalgo et al., 2001;
Woodburn, 1999).
A number of studies suggest that inappropriate ligand-
dependent ErbB2 activation may play a major role in driving
tumor growth or survival pathways (Tzahar and Yarden, 1998).
To further explore these observations, we utilize an antibody,
2C4, that targets ErbB2 and disrupts ligand activation. The pri-
mary focus of this investigation was on breast and prostate
cancer lines that do not overtly overexpress ErbB2 and therefore
would not be targets for therapeutic agents such as trastuzu-
mab. We demonstrate that 2C4 is effective in suppressing the
growth of a number of xenografted tumors that do not overex-
press ErbB2.
Results
2C4 blocks the association of ErbB2 with ErbB3
Since ErbB3 lacks intrinsic tyrosine kinase activity, it is incapable
of initiating productive signaling without interacting with another
receptor tyrosine kinase. In most cases, this receptor is ErbB2
(Graus-Porta et al., 1997; Klapper et al., 1999). We studied
whether ErbB3-ErbB2 complexes exist on the plasma mem-
brane in the absence of the ErbB3 ligand, HRG. To answer this
question, cell lines expressing ErbB3 and ErbB2 were treated
Figure 1. 2C4, but not trastuzumab, blocks the association of ErbB2 withwith HRG or control buffer. Cells were then lysed and immuno-
ErbB3 in breast cancer cell lines that express normal/low and high ErbB2precipitations were performed with an anti-ErbB2 antibody that
levelsrecognizes the intracellular domain of ErbB2. The immunopre-
A: MCF7 (top), which expresses ErbB3 and low or normal levels of ErbB2,cipitates were then subjected to SDS-PAGE and transferred to
and SK-BR-3 (bottom), which expresses ErbB3 and overexpresses ErbB2 at
a nitrocellulose membrane for Western blotting using an anti- high levels, were treated with HRG or control buffer. ErbB3 was found in
ErbB3 monoclonal antibody. The cell lines used for these experi- ErbB2 immunoprecipitates only when MCF7 cells are treated with the ErbB3
ligand HRG. A similar result is obtained when immunoprecipitates are pre-ments were MCF7, which expresses low or normal levels of
pared from the high ErbB2-expressing cell line SK-BR-3. B: A model for theErbB2, and SK-BR-3, which overexpresses ErbB2. As shown
proposed mechanism of 2C4 activity.
Figure 1A, ErbB3 is found in ErbB2 immunoprecipitates only
when MCF7 cells are treated with the ErbB3 ligand HRG. A
similar result is obtained when immunoprecipitates are prepared
from the high-ErbB2-expressing cell line SK-BR3 (Figure 1A). be therapeutically active in the treatment of metastatic breast
These data suggest that the recruitment of ErbB2 to ErbB3 cancer patients whose tumors overexpress ErbB2, and 2C4,
occurs in a HRG-dependent manner. Moreover, even in cell lines which has been shown to ablate HRG-mediated signaling (Lewis
that overexpress ErbB2, such as SK-BR3, little or no preformed et al., 1996; Sliwkowski et al., 1994). Crossblocking studies, as
complexes can be detected. Thus, the formation of the ErbB3- well as epitope-mapping studies, have shown that trastuzumab
HRG-ErbB2 complex occurs sequentially, i.e., ErbB3 binds HRG and 2C4 bind to distinct epitopes on the extracellular domain
and then, in a second reaction, ErbB2 is added to the complex. of the ErbB2 receptor (Fendly et al., 1990). More recently, it
Alternatively, ErbB2 and ErbB3 may form a transient complex was demonstrated that trastuzumab inhibits ErbB2 ectodomain
in the absence of HRG but the association may be too weak cleavage by matrix metalloproteases, whereas 2C4 does not
to allow detection of the receptor complex. HRG binding may (Molina et al., 2001). As shown in Figure 1A, 2C4 is far more
serve to stabilize the ErbB2-ErbB3 complex once it has formed. effective in disrupting ligand-mediated ErbB3-ErbB2 complex
We then studied whether antibodies to the extracellular do- formation than trastuzumab or a control antibody. It is notewor-
main of ErbB2 were capable of disrupting the formation of thy that the 2C4-mediated disruption of this receptor complex
ErbB3-HRG-ErbB2 complexes. Two antibodies to ErbB2 were is independent of ErbB2 expression levels, in that it is effective
in blocking receptor complex formation in both low- and high-used in these studies, trastuzumab, which has been shown to
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Figure 2. 2C4 inhibits ligand activation of ErbB2
in the breast cancer cell line MCF7
A: The monoclonal antibody 2C4, but not trastu-
zumab or control antibody, blocks HRG-induced
tyrosine phosphorylation in whole cell lysates. B:
Whole cell lysates were immunoprecipitated
as described in Figure 1 and then probed for
anti-phosphotyrosine. C: HRG- or TGF-induced
MAPK activation are inhibited by 2C4 but not by
trastuzumab. D: HRG-dependent Akt activation
is inhibited by 2C4 and not trastuzumab. E: Inhibi-
tion of 125I-HRG binding by 2C4 or 2C4-Fab. F:
Inhibition of ErbB3-ErbB2 tyrosine phosphorylation
by 2C4 or 2C4-Fab. The phosphorylation signal
at 180 kDa was quantified by densitometry as
described previously (Lewis et al., 1996).
ErbB2-expressing cell lines. Based on the data presented, a mab. To verify the identity of ErbB2, MCF7 cell lysates were
model for the disruption of ligand-dependent ErbB2 signaling immunoprecipitated with antibodies directed to a cytoplasmic
by 2C4 is proposed in Figure 1B. epitope of ErbB2, and immunoblots were probed for phospho-
tyrosine (Figure 2B). Consistent with the results shown in Figure
2A, 2C4 treatment blocks the appearance of a HRG-dependent2C4 diminishes ligand-activated ErbB2 signaling
phosphorylation signal of ErbB2, whereas trastuzumab doesin breast cancer cell lines
not.Since ErbB3 requires the association with ErbB2 to initiate signal
A downstream target of ErbB2 activation is MAPK (Erk 1transduction, we determined the effect of anti-ErbB2 mono-
and Erk 2). To assess the effect of anti-ErbB2 MAbs on MAPKclonal antibodies on receptor activation. The MCF7 breast can-
activation, MCF7 cells were treated, as described above, andcer cell line was treated with HRG in the presence or absence
MAPK activation was measured using a phospho-specificof anti-ErbB2 monoclonal antibodies. As shown in Figure 2A,
MAPK antibody (Figure 2C). Cells treated with HRG or TGFa number of tyrosine phosphorylated proteins are detected in
show strong activation of MAPK. This activation is diminishedwhole-cell lysates of HRG-treated MCF7 cells. The prominent
with 2C4 treatment and to a much lesser degree with trastuzu-band at180 kDa is known to be a mixture of ErbB3 and ErbB2
mab. These data suggest that ErbB2 association with either(Sadick et al., 1996; Sliwkowski et al., 1994). The phosphoryla-
ErbB3 or EGFR is critical for complete activation of signal trans-tion of these bands is blocked by 2C4 treatment. In contrast,
little if any decrease was observed in cells treated with trastuzu- duction to MAPK. This conclusion is in accordance with previous
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Figure 3. Effect of 2C4 on breast tumor cell
growth in vitro and in vivo
A–D: The response of (A) MCF7, (B) MDA-134,
(C) T47D, and (D) ZR-75-1 monolayer cell culture
growth to the addition of 2C4 with and without
the ligands HRG and EGF. Results are shown as
percentage of control cell proliferation. E and F:
The response of (E) BT474 and (F) MCF7 breast
cancer xenograft tumors to 2C4 (), trastuzu-
mab (H17009), and control () are shown. Arrow indi-
cates the initiation of therapy. Results are given
as mean tumor volume  SE.
reports demonstrating that ErbB2 is a potent activator of the effect of intact 2C4 or a Fab version of 2C4 on 125I-HRG binding
to MCF7 cells (Lewis et al., 1996). Both versions of 2C4 areRas/Raf/MAPK pathway (Marte et al., 1995; Pinkas-Kramarski
et al., 1996a). effective in blocking high-affinity 125I-HRG binding. To further
Due to the presence of six YXXM motifs, ErbB3 is a very characterize the requirement for bivalency, we measured the
potent activator of the PI3 kinase cascade (Soltoff et al., 1994). ErbB2-ErbB3 tyrosine phosphorylation levels in the presence
To address the effect of ErbB2 MAbs on PI3 kinase activation, or absence of 2C4 or the 2C4-Fab. As shown in Figure 2F, both
we measured the activity of the downstream kinase Akt using 2C4 and the 2C4-Fab block the HRG-stimulated phosphoryla-
a synthetic fusion protein derived from GSK3/. As seen in tion of the ErbB2-ErbB3 complex. In this assay format, the
Figure 2D, treatment of MCF7 cells with the ErbB3 ligand, HRG, 2C4-Fab is less potent than the intact antibody. A possible
results in activation of Akt that is inhibited by the pretreatment explanation for this effect may be the increased avidity expected
with 2C4, but not by pretreatment with trastuzumab. for the intact, bivalent antibody in comparison to the monovalent
To determine whether 2C4 must be bivalent in order to Fab fragment.
prevent ErbB2’s recruitment into HRG-ErbB3 complexes, we
assessed the properties of a monovalent Fab version of 2C4. 2C4 inhibits the growth of human breast cancer
cell lines only in the presence of ligandA characteristic of an ErbB3-ErbB2 complex is the formation
of a high-affinity HRG binding site (Fitzpatrick et al., 1998; Sliw- The ability of 2C4 to inhibit the in vitro proliferation of low-ErbB2-
expressing breast tumor cells was studied. The expression ofkowski et al., 1994). As shown in Figure 2E, we examined the
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ErbB2 and other ErbB receptors in these breast cancer cell lines
was reported by deFazio et al. (2000). As demonstrated in Figure
3, 2C4 does not directly inhibit growth of MCF7 (Figure 3A),
MDA-MB-134 (Figure 3B), T-47D (Figure 3C), or ZR-75-1 (Figure
3D) cells compared to untreated cells. However, when the cells
are treated with the ErbB ligand HRG, there is significant growth
stimulation (between 155% and 230% of control growth), which
is inhibited in all cases by treatment with 2C4. Exposure of the
cells to EGF resulted in modest growth induction, which was
also inhibited by 2C4 in the MCF7, MDA-MB-134, and ZR-75-1
breast tumor cells.
2C4 inhibits the growth of low- and high-ErbB2-
expressing human breast cancer xenograft tumors
To further examine the effect of 2C4 treatment on tumor cell
growth, animals with established BT474 (high-ErbB2) or MCF7
(low-ErbB2) breast cancer xenograft tumors were administered
anti-ErbB2 antibodies. Growth inhibition was demonstrated in
the high-ErbB2 xenografts with both trastuzumab and 2C4 com-
pared with control-treated tumors (trastuzumab, 77% growth
inhibition, p  0.004, n  6; 2C4, 80% growth inhibition, p 
0.001, n  10; Figure 3E). The results with trastuzumab are
similar to those reported previously (Baselga et al., 1998). In
experiments not shown here, 2C4 also inhibits the growth of
several ErbB2 overexpressing tumor xenograft models including
MCF7 cells transfected to overexpress ErbB2, MDA-MB-361
(which displays moderate or 2 ErbB2 overexpression), and
the lung adenocarcinoma cell line, CALU-3. We conclude that
2C4 shares trastuzumab’s (or 4D5’s) inhibitory activity toward
models in which tumor growth is driven by ligand-independent
ErbB2 activation. As expected (Pegram et al., 1999), trastuzu-
Figure 4. 2C4 inhibits HRG activation of MAPK or Akt in androgen-depen-mab did not inhibit growth of the low-ErbB2 tumors compared
dent (CWR22v1) and androgen-independent (CWR22Rv1) prostate cancerwith control-treated tumors, but in this study there was signifi-
cell linescant growth inhibition by 2C4 in this treatment group (59%
A: HRG-induced MAPK activation and HRG-dependent Akt activation isgrowth inhibition, p  0.001, compared with controls or trastu-
inhibited by rhuMAb 2C4. B: The response of CWR22Rv1 monolayer cell
zumab-treated groups, n  12; Figure 3F). culture growth to the addition of 2C4 with and without rHRG1 or EGF is
shown. Results are shown as percentage of control cell proliferation.
2C4 diminishes ligand-activated ErbB2 signaling
in both androgen-dependent and -independent
prostate cancer cell lines
Akt. As seen in Figure 4A, similar to the MCF7 cells, treatmentA number of studies suggest that ErbB receptor activation may
of both 22v1 and 22Rv1 cells with the ErbB3 ligand, HRG, resultsbe important in the growth and survival of both androgen-
in activation of Akt that is inhibited by treatment with 2C4.dependent and androgen-independent prostate cancer (Agus
The ability of 2C4 to inhibit the in vitro proliferation of theet al., 2000; Kim et al., 1999). Therefore, 2C4 was evaluated in
22Rv1 (androgen-independent) cell line was studied. As demon-both in vitro and in vivo prostate cancer models. Similar to
strated in Figure 4B, 2C4 does not inhibit growth of 22Rv1 cellsthe experiments using breast cancer cell lines, HRG-activated
compared with untreated cells (p  0.86). However, when cellsreceptor phosphorylation levels were significantly decreased in
are treated with HRG or EGF, there is significant growth induc-prostate cancer cells that were pretreated with 2C4 in both
tion (172% and 153% of control for HRG and EGF, respectively)the androgen-dependent (22v1) and androgen-independent
(22Rv1) prostate cancer cell lines (data not shown). Neither of that can be inhibited by treatment with 2C4.
these cell lines overexpress ErbB2. The effect of 2C4 treatment
on MAPK activation in both the androgen-dependent and andro- 2C4 inhibits the growth of both androgen-dependent
and androgen-independent human prostategen-independent prostate cancer cells was studied (Figure 4A).
Cells treated with HRG show strong activation of MAPK. This cancer xenografts
To determine if our in vitro observations translated into tumoractivation is diminished with 2C4 treatment in both the andro-
gen-dependent and androgen-independent strains. These data growth inhibition, we evaluated the efficacy of 2C4 on the growth
of the androgen-independent prostate cancer xenograft CWR22R.suggest that ErbB2 association with ErbB3 is critical for com-
plete activation of signal transduction to MAPK in prostate can- As shown in Figure 5A, three different versions of 2C4 were
tested including the murine version (muMAb 2C4) and a fullycer cells, similar to the data described in the breast cancer
experiments. The effect of ErbB2 MAbs on PI3 kinase activation humanized variant (rhuMAb 2C4) (C. Adams, D. Allison, J. Clark,
B. Fan, T. Breece, C. Schmelzer, S. Brignoli, K. Totpal, G. Phil-was measured by studying the activity of the downstream kinase
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dent tumor. We conclude that the 2C4-mediated growth inhibi-
tion of the tumors was not through an immunologic mechanism,
as intact Fc region was not required for tumor growth inhibition.
The dose response relationship for CWR22R tumor growth inhi-
bition by rhuMAb 2C4 is shown in Figure 5B. In this study,
animals were administered a loading dose to more rapidly sus-
tain rhuMAb 2C4 blood levels. Maximum growth inhibition was
achieved with a loading dose of 60 mg/kg followed by weekly
doses of 30 mg/kg. This dose response relationship is similar
to that reported with trastuzumab and the ErbB2-transfected
MCF7 cell line (Pietras et al., 1998). The growth of a second
androgen-independent model, CWRSA6 (Agus et al., 1999b),
was also examined for sensitivity to rhuMAb 2C4 (Figure 5C).
As reported previously (Agus et al., 1999c), trastuzumab had
no effect on CWRSA6 tumor growth when compared to control
(data not shown, p  0.63, n  10). In contrast, rhuMAb 2C4
demonstrated significant tumor growth inhibition relative to con-
trol-treated animals (CWRSA6, 82% growth inhibition, p 
0.0047, n  10). To determine whether rhuMAb 2C4 also inhib-
ited the growth of androgen-dependent prostate tumors, three
different models were tested (Figure 6). rhuMAb 2C4 demon-
strated tumor growth inhibition in the androgen-dependent
models of prostate cancer. At the doses and schedules tested,
the degree of inhibition for trastuzumab (Agus et al., 1999c) and
rhuMab 2C4 was similar. For trastuzumab (data not shown),
growth inhibition observed with CWR22 was 68% (p  0.003,
n  12), LNCaP was 89% growth inhibition (p  0.002, n 
12), and LuCaP35 was 78% (p  0.002, n  12). rhuMAb 2C4
treatment demonstrated similar growth inhibition. With the
CWR22 xenograft (Figure 6A), 93% growth inhibition was ob-
served (p  0.0001); with LNCaP (Figure 6B), there was 83%
growth inhibition (p  0.001); and with LuCaP35 (Figure 6C),
there was 90% growth inhibition (p  0.001). None of the pros-
tate cancer models used in this study overexpress ErbB2 in
comparison to breast tumors with known ErbB2 gene amplifica-
tion or breast cancer cell lines such as BT-474 or SK-BR-3
(Agus et al., 1999c).
Expression of ErbB receptors and ligands in androgen-
dependent and -independent tumor explants
Since the ErbB pathway is thought to be activated in the pro-
gression from androgen dependence to androgen indepen-
dence (Craft et al., 1999; Scher et al., 1995), we examinedFigure 5. Effect of 2C4 on androgen-independent prostate tumor xeno-
relative ErbB receptor and ligand expression in the androgen-grafts
dependent and androgen-independent tumors. Since the ge-A: The response of CWR22R tumors to murine 2C4 (muMAb 2C4) (), human
2C4 (rhuMAb 2C4) (), a polyethylene glycol derivative of the human 2C4 netic background of the CWR tumors is similar (Nagabhushan
Fab (H17009), or control Mab (). Arrow indicates the initiation of therapy. B: et al., 1996), the ratio of gene expression in CWR22R to the
Dose response of rhuMAb 2C4 treatment using the CWR22R model. Tumor- parental CWR22 and CWRSA6 to CWR22 was measured. Abearing animals were treated with an isotype control antibody (); 6 mg/
summary of this analysis was made for the four ErbB receptorskg of rhuMAb 2C4 followed by two weekly injections at 3 mg/kg (); 20
mg/kg of rhuMAb 2C4 followed by two weekly injections at 10 mg/kg (); and four ligands (Figure 7). Interestingly, the androgen-indepen-
or 60 mg/kg of rhuMAb 2C4 followed by two weekly injections at 30 mg/ dent tumors appear to express higher levels of three EGFR
kg (H17009). C: CWRSA6 treated with rhuMAb 2C4 or trastuzumab, each adminis- ligands. Specifically, CWR22R expresses19-fold and9-fold
tered at 20 mg/kg, twice per week.
higher levels of HB-EGF and TGF, respectively, relative to
CWR22. In contrast, CWRSA6 expresses 9-fold and 5-fold
levels of HB-EGF and EGF, respectively.
lips, L. Presta, and M.X.S. unpublished data). In addition, we
Discussionalso tested a Fab version of rhuMAb 2C4 that was derivatized
with polyethylene glycol (PEG-Fab) to allow for a longer serum
In previous reports, we investigated the role of ligand-activatedhalf-life. In contrast to previous experiences with trastuzumab
ErbB2 on the in vitro growth of various breast cancer cell lines(Kelley et al., 1992), all versions of 2C4, including the monovalent
Fab version, suppressed the growth of the androgen-indepen- (Lewis et al., 1996; Schaefer et al., 1997). The present study
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Figure 7. Real-time quantitative reverse-transcription PCR analysis of expres-
sion of ErbB receptors and ligands
Gene expression is plotted for the ratio of CWR22R/CWR22 and CWR22SA6/
CWR22. Assays were performed in triplicate and the average is shown.
gest that activation of the ErbB kinase axis results in androgen
receptor activation (Kim et al., 1999). Some of the molecular
details defining these signal transduction pathways are begin-
ning to emerge. For example, ErbB2 activation can lead to
androgen target gene expression through activation of the
MAPK pathway (Yeh et al., 1999). More recently it has been
reported that a constitutively active mutant form of ErbB2 leads
to Akt activation and the androgen receptor is a substrate for
Akt (Wen et al., 2000). ErbB2 activation through Akt to the
androgen receptor is proposed as a major pathway that pro-
motes androgen-independent prostate cancer growth and sur-
vival. At present the mechanisms by which ErbB2 becomes
activated in prostate cancer are unclear. Several reports sug-
gested that ErbB2 gene amplification was common in prostate
cancer (Kallakury et al., 1998; Ross et al., 1997). However, a
number of recent studies have failed to confirm these initial
findings (Oxley et al., 2002; Reese et al., 2001; Savinainen et
Figure 6. Effect of 2C4 on androgen-dependent prostate tumor xenografts al., 2002). An alternative scenario has suggested that excess
The response of CWR22 (A), LNCaP (B), or LuCap 35 (C) tumors to rhuMAb ErbB2 protein synthesis or decreased protein degradation may
2C4 () or isotype control antibody (), each administered at 20 mg/kg
take place in the absence of gene amplification. Moreover, thetwice per week. Arrow indicates the initiation of therapy. Results are given
onset of ErbB2 protein overexpression may coincide with theas mean tumor volume (n  8)  SE.
emergence of androgen independence. Experimental evidence
for this possibility has been demonstrated by Craft et al. (1999)
with the prostate cancer cell line LNCaP. Recently it was re-
extends these observations and further examines the role of ported that a similar phenomenon may occur in prostate cancer
ligand-activated ErbB2 signaling in breast and prostate tumor patients (Osman et al., 2001; Shi et al., 2001; Signoretti et al.,
models. The developing and adult prostate is regulated by an- 2000).
drogen, a feature shared by most early forms of prostate cancer. In the present study, we adopted an alternative strategy to
Disease progression is the result of the emergence of an andro- targeting ErbB receptors that is geared toward disrupting the
gen-independent phenotype (Grossmann et al., 2001). Although recruitment of ErbB2 into ErbB receptor-ligand complexes. The
these tumor cells still express androgen receptor, the respon- ramifications of our approach are dependent upon the particular
siveness of the receptor to agonists or antagonists is frequently repertoire of ErbB receptors expressed by the tumor. In the
altered. A number of recent studies have demonstrated that case of EGFR, which is fully functional as a tyrosine kinase,
androgen receptor activation can also occur as a result of pep- blocking the recruitment of ErbB2 into EGFR-ligand complexes
does not ablate signaling but dampens the diversity, intensity,tide growth factor activation (Wells, 1999). Several reports sug-
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and duration of signaling (Beerli and Hynes, 1996; Graus-Porta growth in vivo suggest that biological activity is not dependent
et al., 1997; Karunagaran et al., 1996). A number of biochemical on bivalency or the presence of an Fc region. To facilitate clinical
and biological explanations have been put forward to help inte- investigations in cancer patients, the pharmacokinetic and toxi-
grate the role that ErbB2 plays in complex with EGFR. Thus, in cological properties of an intact, humanized variant of 2C4 was
comparison to when EGFR is expressed alone, the EGFR-ErbB2 examined in nonhuman primates (C. Adams, D. Allison, J. Clark,
complex exhibits higher ligand affinities (Jones et al., 1999; B. Fan, T. Breece, C. Schmelzer, S. Brignoli, K. Totpal, G. Phil-
Karunagaran et al., 1996), a more complex and diverse initiation lips, L. Presta, and M.X.S., unpublished data). The results of
of signal transduction pathways (Olayioye et al., 1998; Pinkas- these preclinical studies suggest that rhuMAb 2C4 behaves very
Kramarski et al., 1996b), decreased rate of endocytosis (Wor- similar to trastuzumab with regard to pharmacokinetic proper-
thylake et al., 1999), and altered receptor complex trafficking ties. Disrupting ligand-activated ErbB2 may complement other
(Lenferink et al., 1998). EGFR-ligand complexes containing strategies devised to target ErbB signaling in human neoplasms.
ErbB2 exhibit a longer duration of signaling due to the fact that
the complexes remain at the cell surface longer. Although a role Experimental procedures
for ErbB4 in most solid tumors is ill defined, it is likely those
Cell and tumor linesramifications of ErbB2 in complex with ErbB4 are similar to that
The 22v1 and 22Rv1 cell strains were obtained by mincing CWR22/CWR22Robserved with EGFR.
xenografts, placing the cells into 6-well matrigel basement membrane matrixIn contrast, the inhibition of association of ErbB2 with ErbB3
coated dishes (Biocoat cell environments, Becton Dickinson, Franklin Lakes,results in the near complete absence of receptor complex sig-
NJ) containing Dulbecco’s modified Eagle’s medium, supplemented withnaling (Beerli et al., 1994, 1995; Guy et al., 1994). The analysis
10% heat-inactivated FBS, 100 U/ml penicillin, and 0.1 mg/ml streptomycin
of clinical specimens derived from human tumors indicates that (GIBCO-BRL, Rockville, MD) and incubating at 37C, 5% CO2, in a humidified
the dynamic range of ErbB3 expression seems to be narrower atmosphere for 3–4 days to allow for cell attachment. Following the initial
than that observed for either EGFR or ErbB2. A teleological incubation, the media was replaced with minimal essential medium con-
reason for this observation may be ErbB3’s lack of tyrosine taining D-val (MEM D-val, ATCC, Manassas, VA) supplemented with 10%
heat-inactivated FBS, 100 U/ml penicillin, and 0.1 mg/ml streptomycinkinase activity, which, if upregulated, would not convey a growth
(GIBCO-BRL). The CWR22/CWR22R cells were then allowed to grow for 4advantage to the tumor because it lacks the ability to signal
weeks or until only the epithelial cells remained. The MCF7, MDA-MB-134,autonomously. Instead, we hypothesize that inappropriate li-
T47D, and ZR-75-1 breast tumor cell lines and 22Rv1 prostate carcinomagand activation of ErbB3-ErbB2 signaling may play an important
line were obtained from the American Type Culture Collection (Manassas,role in tumor growth. Support for this hypothesis lies in the
VA) and used for proliferation studies. Cells were maintained in high-glucose
observation that ErbB3 expressed together with ErbB2 is the DMEM:Ham’s F-12 (50:50) supplemented with 10% heat-inactivated FBS
most potent ErbB complex with regard to receptor signaling and 2 mM l-glutamine. For proliferation assays, cells were seeded into 96-
(Pinkas-Kramarski et al., 1996a). Moreover, the transformation well microtiter plates at a density of 104 cells per well and allowed to adhere
potential of ErbB2-ErbB3 is also far greater than that observed overnight. The media were then replaced with low-serum media (1% FBS) 
rhuMAb 2C4 at a concentration of 100-fold molar excess over ligand concen-for any other ErbB receptor complex (Alimandi et al., 1995;
tration (30 nM rhuMAb 2C4 for 22Rv1 and 300 nM for MCF7, MDA-134,Wallasch et al., 1995).
T47D, and ZR-75-1). The cells were allowed to sit at room temperature forSince ErbB2 functions as a coreceptor with other ErbB fam-
2 hr, after which the ErbB ligands HRG-1 (0.3 nM) or EGF (3 nM for MCF7,ily members, overexpression of the receptor is not required
0.3 nM for 22Rv1) were added. Following a 3 day incubation, cell monolayersfor signaling if ErbB ligands are available to drive biological
were washed with PBS and stained with crystal violet dye for determination
responses. Here we tested this notion directly using an antibody of relative cell proliferation as previously described (Lewis et al., 1996).
directed against ErbB2 that appears to sterically block the asso- The xenograft studies were performed as previously described (Agus
ciation of ErbB2 with other ErbB family members. Using this et al., 1999b, 1999c). Four- to six-week-old nude athymic BALB/c male and
approach, we demonstrate that ErbB2 activation may play a female mice were obtained from the National Cancer Institute-Frederick
Cancer Center and maintained in pressurized ventilated caging at the Ce-critical role in driving the growth and survival of human breast
dars-Sinai Medical Center vivarium. Male animals were inoculated subcuta-and prostate tumor xenografts. At present, we are uncertain
neously with 1 107 LNCaP cells or minced tumor tissue from the androgen-about several details regarding ErbB activation. Our failure to
dependent CWR22 (gift from T. Pretlow) and LuCaP (gift from R. Vessela),detect 2C4 effects, in the absence of exogenous ligand addition,
and females received the androgen-independent sublines CWR22R,on low-ErbB2-expressing cell lines derived from our tumor mod-
CWRSA1, or CWRSA6, which were obtained by selecting tumors for re-els suggests that the growth of these cell lines in vitro is not
growth and increased serum PSA after androgen withdrawal (Agus et al.,
driven by autocrine production of ErbB ligands. A likely source 1999a). Female mice were inoculated with 1  107 MCF7 cells. All lines
of ligand production is the tumor stroma. Stroma-epithelial inter- were injected together with reconstituted basement membrane (Matrigel;
actions have been studied extensively with regard to breast and Collaborative Research, Bedford, MA), as described previously (Nagabhu-
prostate development (Chung, 1993; Cullen and Lippman, 1992; shan et al., 1996; Wainstein et al., 1994). To maintain serum testosterone
or estrogen (for the MCF-7 line) levels, mice were implanted with 12.5 mgCunha, 1994). Several ErbB ligands are known to be expressed
sustained release testosterone pellets or 0.72 mg sustained release 17in prostate and may be differentially expressed in prostate tu-
-estradiol pellets (Innovative Research of America, Sarasota, FL) subcuta-mors (Scher et al., 1995; Adam et al., 1999; Duque et al., 2001;
neously before receiving the tumor cell inoculation. Treatments consisted ofTorring et al., 2000). We surmise that disrupting ErbB signaling
twice weekly intraperitoneal injection of 20 mg/kg trastuzumab (Herceptin,by 2C4 may account for the inhibition of tumor growth.
rhuMAb ErbB2, trastuzumab, Genentech, Inc., South San Francisco, CA) or
In conclusion, we demonstrate that an antibody, 2C4, di-
2C4 (Genentech) in PBS for no less than 3 weeks. Control mice were given
rected against ErbB2, disrupts its role as a coreceptor and vehicle alone. Tumors were measured every 3–4 days with vernier calipers,
exhibits promising activity in models of breast and prostate and tumor volumes were calculated by the formula: 	/6  larger diameter 
cancer. The observations that monovalent versions of 2C4 are (smaller diameter)2. Animals with palpably established tumors of at least 65
mm3 in volume were designated to treatment groups.also effective in blocking ErbB2 function in vitro and tumor
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MAP kinase (MAPK) and Akt assays using real-time quantitative PCR (TaqMan, ABI PRISM 7700, Applied Biosys-
tems, Foster City, CA) technique, as previously described (Gibson et al.,To assess MAPK phosphorylation, cells (105/well) were plated in serum-
containing media in 12-well culture plates. The next day, media were re- 1996; Heid et al., 1996). The sequences of the primer/probe sets used for
this analysis are as follows. F and R are the forward and reverse prim-moved and fresh media containing 0.1% serum were added to each well.
This procedure was then repeated the following day, and prior to assay the ers, respectively, and P is the fluorescent-labeled probe. EGFR: (F)
5
-TTCCTGTGGATCCAGAGGA-3
, (R) 5
-AGCGTAATCCCAAGGATGT-3
,media were replaced with serum-free binding buffer (Jones et al., 1998).
Cells were allowed to equilibrate to room temperature and then incubated (P) 5
-FAM-AGGACGGACCTCCATGCCTTTGAGAA-TAMARA-p-3
; ErbB2/
neu: (F) 5
-TCTGGACGTGCCAGTGTGAA-3
, (R) 5
-TGCTCCCTGAGGACAfor 30 min with 0.5 ml of 200 nM trastuzumab or 2C4. Cells were then treated
with 1 nM EGF or TGF or 0.2 nM rHRG1177–244 (rHRG1) for 15 min. The CATCA-3
, (P) 5
-FAM- CAGAAGGCCAAGTCCGCAGAAGCC-TAMARA-p-
3
; ErbB3: (F) 5
-TTCTCTACTCTACCATTGCCCAAC-3
, (R) 5
-CACCACreaction was stopped by aspirating the cell medium and then adding 0.2
ml SDS-PAGE sample buffer containing 1% DTT. MAPK activation was TATCTCAGCATCTCGGTC-3
, (P) 5
-FAM-ACACCAACTCCAGCCACGCT
CTGC-TAMARA-p-3
; ErbB4: (F) 5
-GAGATAACCAGCATTGAGCACAAC-assessed by Western blotting using an anti-active MAPK antibody (Promega,
3
, (R) 5
-AGAGGCAGGTAACGAAACTGATTA-3
, (P) 5
-FAM-CCTCTCCMadison, WI) as described previously (Jones et al., 1998).
TTCCTGCGGTCTGTTCGA-TAMARA-p-3
; EGF: (F) 5
-AGCTAACCCATFor Akt activation, 10 cm dishes seeded the night before with 3  106
TATGGCAACA-3
, (R) 5
-AGTTTTCACTGAGTCAGCTCCAT-3
, (P) 5
-FAM-cells/dish were incubated for 3 hr in serum-free media. The cells were then
AGGGCCCTGGACCCACCAC-TAMARA-p-3
; TGF: (F) 5
-GGACAGCACTincubated an additional hour in serum-free media containing either 2C4 or
GCCAGAGA-3
, (R) 5
-CAGGTGATTACAGGCCAAGTAG-3
, (P) 5
-FAM-trastuzumab at a concentration of 100 nM, or in serum-free media without
CCTGGGTGTGCCACAGACCTTC-TAMARA-p-3
; HRG: (F) 5
-TGGCTGACadditions (control). Ligand stimulation was carried out using 1 nM rHRG1
AGCAGGACTAAC-3
, (R) 5
-CTGGCCTGGATTTCTTC-3
, (P) 5
-FAM-CAGfor 12 min. Akt activity was determined with an assay kit (Cell Signaling
CAGGCCGCTTCTCGACAC-TAMARA-p-3
; HB-EGF: (F) 5
-GAAAGACTTCTechnology) based on phosphorylation of GSK-3/. GSK-3 is a natural
CATCTAGTCACAAAGA-3
, (R) 5
-GGGAGGCCCAATCCTAGA-3
, (P) 5
-substrate of the Akt kinase. Cell lysates were prepared and processed ac-
FAM-TCCTTCGTCCCCAGTTGCCG-TAMARA-p-3
.cording to the kit manufacturer’s directions. Briefly, immunoprecipitations
Ribosomal protein 19 (RPL19) was used as a housekeeping gene forwere performed on the cell lysates using an immobilized anti-Akt affinity gel.
EGFR family receptor genes. Primer/probe sets for RPL19 are (F) 5
-ATGThe washed immunoprecipitates were then resuspended in a kinase buffer
TATCACAGCCTGTACCTG-3
, (R) 5
-TTCTTGGTCTCTTCCTCCTTG-3
, andand incubated with a recombinant fusion protein that contains a portion of
(P) 5
-FAM-AGGTCTAAGACCAAGGAAGCACGCAA-TAMRA-p-3
.the GSK-3/ sequence. Supernatants from these incubations were diluted
-actin was used as a housekeeping gene for the EGFR family ligands.in SDS-sample buffer, and phosphorylation of the fusion protein was as-
Primer/probe sets for -actin, listed here, were obtained from PE Appliedsessed by Western blot using an antibody specific for phosphorylation of
Biosystems (Foster City, CA): (F) 5
-TCACCCACACTGTGCCCATCTACGA-3
,GSK-3 at Ser21 or GSK-3 at Ser9.
(R) 5
-CAGCGGAACCGCTCATTGCCAATGG-3
, and (P) 5
-FAM-ATGCCCX
(TAMARA)CCCCCATGCCATC-p-3
.Immunoprecipitation
TaqMan analysis was performed in a standard 96-well plate format.The ability of ErbB3 to associate with ErbB2 was tested in a coimmunopreci-
Standard curves were constructed using 3.9–1000 ng of total mRNA pre-pitation experiment. MCF-7 or SKBR-3 cells (106 cell/well) were seeded in
pared from cultured cells of T47D for EGF and receptor genes and MDA-6-well tissue culture plates in 50:50 DMEM/Ham’s F12 medium containing
MB-231 for all other ligands and 31.25–500 ng for RPL19. Each dilution was10% fetal bovine serum and 10 mM HEPES (pH 7.2) (growth medium) and
run in duplicate. All samples were run in triplicate using 100 ng of mRNAallowed to attach overnight. The cells were starved for 2 hr in growth medium
for each reaction.without serum prior to beginning the experiment. The cells were washed
briefly with PBS and then incubated with either 100 nM of the indicated
Statistical analysis of the xenograft experimentsantibody diluted in 0.2% w/v BSA, RPMI medium, with 10 mM HEPES (pH
Pairwise differences between the tumor volumes of the treatment groups7.2) (binding buffer), or with binding buffer alone (control). After 1 hr at room
were compared over time using a permutation test. The null hypothesis fortemperature, rHRG1 was added to a final concentration of 5 nM to half
this test is that treatment has no differential effect on the tumor volumesthe wells and a similar volume of binding buffer was added to the other
over time. The statistic (SS_Dev) used to test the hypothesis was the sumwells. The incubation was continued for approximately 10 min. Supernatants
of the squared differences between mean tumor volume summed over allwere removed by aspiration, and the cells were lysed in RPMI, 10 mM
time points. This statistic reflects the amount by which the trajectories ofHEPES (pH 7.2), 1.0% v/v Triton X-100, and 1.0% w/v CHAPS (lysis buffer)
average tumor volume of the two treatment groups are different (Agus etcontaining 0.2 mM PMSF, 10 g/ml leupeptin, and 10 U/ml aprotinin. The
al., 1999c).lysates were cleared of insoluble material by centrifugation.
ErbB2 was immunoprecipitated using a monoclonal antibody covalently
Acknowledgmentscoupled to an affinity gel (Affi-Prep 10, Bio-Rad, Hercules, CA). This antibody
(Ab-3, Oncogene Sciences, Boston, MA) recognizes a cytoplasmic domain
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l of gel slurry
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containing approximately 8.5 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were then collected by centrifugation. The gels were washed batch-wise
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three times with lysis buffer to remove unbound material. SDS sample buffer
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was then added and the samples were heated briefly in a boiling water bath.
Supernatants were run on 4%–12% polyacrylamide gels and elec-
troblotted onto nitrocellulose membranes. The presence of ErbB3 was as-
sessed by probing the blots with a polyclonal antibody against a cytoplasmic
Received: June 14, 2002domain epitope (c-17, Santa Cruz Biotechnology, Santa Cruz, CA). The
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